Eli Lilly and Company (NYSE:LLY) Shares Acquired by WoodTrust Financial Corp

WoodTrust Financial Corp lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,326 shares of the company’s stock after buying an additional 364 shares during the period. WoodTrust Financial Corp’s holdings in Eli Lilly and Company were worth $1,809,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Trexquant Investment LP acquired a new stake in Eli Lilly and Company during the 3rd quarter worth $3,874,000. Morningstar Investment Services LLC raised its stake in Eli Lilly and Company by 112.8% during the 3rd quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock worth $948,000 after acquiring an additional 923 shares in the last quarter. Ancora Advisors LLC raised its stake in Eli Lilly and Company by 2.9% during the 3rd quarter. Ancora Advisors LLC now owns 6,935 shares of the company’s stock worth $3,725,000 after acquiring an additional 198 shares in the last quarter. Gotham Asset Management LLC raised its stake in Eli Lilly and Company by 111.3% during the 3rd quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock worth $3,967,000 after acquiring an additional 3,891 shares in the last quarter. Finally, Kinloch Capital LLC raised its stake in Eli Lilly and Company by 25.8% during the 3rd quarter. Kinloch Capital LLC now owns 717 shares of the company’s stock worth $385,000 after acquiring an additional 147 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.4 %

LLY stock opened at $905.38 on Friday. The company has a market cap of $860.48 billion, a P/E ratio of 133.34, a P/E/G ratio of 1.97 and a beta of 0.36. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $915.54. The company’s 50-day moving average price is $814.40 and its 200 day moving average price is $739.86. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.62 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. Jefferies Financial Group lifted their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Truist Financial restated a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Argus lifted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Bank of America restated a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a research note on Monday, June 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $812.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold 789,704 shares of company stock valued at $672,385,964 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.